Myocardial salvaging effects and mechanisms of dipeptidyl peptidase-IV inhibitor Vildagliptin in experimental diabetes
DOI:
https://doi.org/10.7439/ijbr.v7i5.3273Abstract
Background: Morbidity, mortality and re- infarction rate are higher following myocardial infarction in diabetics than non-diabetic subjects. Recently, glucagon-like peptide (GLP)-1 was shown to have cardioprotective effects, but treatment with GLP-1 is limited by its short half-life. It is rapidly degraded by the enzyme dipeptidyl peptidase-IV (DPP-IV). We hypothesized that DPP-IV inhibitor Vildagliptin will increase levels of GLP-1 and may confer cardioprotective effects in setting of diabetes beyond its effect on glycemia. Objective: The aim of the present study was to investigate potential cardioprotective effects and mechanisms of Vildagliptin subsequent to isoproterenol induced myocardial infarction in the setting of diabetes. Methods: Diabetes was induced with single dose of Streptozotocin (STZ): 45mg/kg ip and myocardial infarction was produced by administering isoproterenol (ISP): (85mg/kg, sc) to rats 24 and 48 h prior to sacrification (5th week). After the confirmation of diabetes on 7th day (Glucose>200mg/dl), Vildagliptin (10 mg/kg) was administered and various parameters like anti-diabetic (Glucose, HbA1c), cardioprotective (CPK-MB, hs-CRP), hypolipidemic (lipid profile, artherogenic potential), antioxidant (MDA) safety {pancreatic function (lipase), liver function (SGPT), kidney function (Creatinine)} and histopathological indices of injury were evaluated in experimental groups. Results : Vildagliptin (10 mg/kg) treatment demonstrated significant antidiabetic as well as myocardial salvaging effects as indicated by restoration of blood glucose, HbA1c and CPK-MB levels compared to Diabetic- ISP Control group. In addition, Vildagliptin favorably modulated the lipid parameters (TC,TG, HDL, LDL), artherogenic index, lipid peroxidation (MDA), Subsequent to ISP challenge, histopathological assessment of heart, pancreas and biochemical indices of injury confirmed the cardioprotective effects of Vildagliptin in setting of diabetes. Conclusion: The present study concluded that Vildagliptin treatment demonstrated myocardial salvaging effects in type II diabetic rats challenged with experimental Myocardial infarction.Downloads
Download data is not yet available.
Downloads
Published
2016-05-30
Issue
Section
Original Research Articles
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- An author must submit Copyright form After acceptance of the article.
How to Cite
1.
Myocardial salvaging effects and mechanisms of dipeptidyl peptidase-IV inhibitor Vildagliptin in experimental diabetes. Int Jour of Biomed Res [Internet]. 2016 May 30 [cited 2026 Feb. 17];7(5):276-82. Available from: https://ssjournals.co.in/index.php/ijbr/article/view/3273